Abstract Submission

[SUBMIT YOUR ABSTRACT](#)

Open

Late-Breaking Abstract Submission Is Open

23 October 2024

Late-Breaking Abstract Submission Deadline*

*Late-breaking Abstract Submission is now open. **The late-breaking abstract submission deadline is on 23 October 2024. Please note that late-breaking abstract submissions will be considered for Poster Presentation only.**
The extended deadline for late-breaking abstract submissions for Poster Presentations was on 23 October 2024.

All submitted abstracts are currently undergoing evaluation by the Abstract Review Committee. All submitters will be notified of the results via email by the middle of November. In case you have any questions, please contact us at reg_icle25@kenes.com indicating your abstract title and/or abstract ID number.

SUBMIT YOUR ABSTRACT AND GET A CHANCE TO BE ON THE ICLE STAGE WITH THE LEADERS IN THE FIELD.

The best abstracts will be presented during the main program sessions. All accepted abstracts will be published in Human Gene Therapy Journal.

GUIDELINES FOR THE SUBMISSION OF

ABSTRACTS

Participants interested in presenting an Oral or Poster presentation are invited to submit an abstract. All abstracts will undergo peer review by the Abstract Review Committee and may be accepted for presentation or rejected. The Committee reserves the right to decide on the final topic allocation and form of presentation.

NB! Please kindly note that any abstract, submitted by an industry representative will be considered as an industry paper. For more information, please visit our [industry presentation section here](#).

PRESENTATION TYPE AVAILABLE FOR THE REGULAR ABSTRACT SUBMISSION CAMPAIGN:

ACADEMIC ORAL PRESENTATION
ACADEMIC POSTER PRESENTATION

ABSTRACT TOPICS

- Real-world experience, novel clinical approaches and combination therapies
- Superpowered lymphocytes
- Non-viral CAR/TCR gene targeting
- CAR/TCR mRNA therapies
- Universal donor cells & Advanced TCR engineering
- Updated clinical data
- Beyond alpha-beta T cells
- Targeting non-malignant diseases
- In vivo and bedside T cell engineering
- Other

GUIDELINES FOR SUBMISSION

- All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality

suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university scientific publications office (or other similar facility) or by a copy editor, prior to submission.

- Abstracts must be submitted via the website only.
- Abstracts submitted by email will not be accepted.
- Please do not submit multiple copies of the same abstract.
- Abstracts must be received by the announced deadline. **No modifications and corrections can be made after the submission deadline.**
- Each person may submit up to 3 abstracts. A person may be listed as **presenting author on up to 3 abstracts.**
- All abstracts will be forwarded to the Abstract Review Committee for review.
- The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final topic allocation and form of presentation. There are limited oral presentation opportunities in the program, those abstracts not accepted for oral presentation will be offered an e-poster or poster presentation.
- You will receive confirmation that your abstract has been received, indicating the abstract number which it has been allocated. Please refer to this abstract number in all correspondence regarding this abstract.
- Please contact the Conference Secretariat if you have not received confirmation that your abstract has been received.
- **Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by 30th October 2024 will be scheduled in the program.**
- Presenting author can be replaced by one of the co-authors only.
- Submission of an abstract acknowledges your acceptance

for the abstract to be published in the official meeting publications.

- Abstracts that have been presented at another meeting may be submitted
- Notifications regarding the status of the abstract will be sent once the review process is complete.
- No changes will be made to submitted and accepted abstracts.
- Conflicts of Interest / Disclosure: Abstract submitters will be requested to confirm that you will declare any conflict of interests in your presentation at the conference.

RULES FOR SUBMISSION

Before you begin, kindly prepare the following information:

Presenting Author contact information;

- Email address
- Full postal address
- Daytime and evening phone number
- Author and co-authors' details
- Full first and family name(s)
- Authors' names must be in upper and lower case (J.C.C. Smith)
- Affiliation information: department, institution / hospital, city state (if relevant), country
- Abstract title – Limited to 25 words in UPPER CASE
- Abstract text – Limited to 250 words
- Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
- Use generic names of drugs. Express numbers as numerals
- You will receive an abstract reference number via email after you have submitted your abstract.
- After submitting your abstract, you can still make changes up until the deadline.

- After the deadline, no changes will be accepted.
- Abstract topic– abstracts must be allocated to a specific topic for the scientific program. You will need to select the category most suited to your abstract.

ABSTRACT SUBMITTERS' DECLARATION

Disclosure of financial relationships that the author(s) may have with the manufacturer/supplier of any commercial products or services related to the work, should be indicated in the appropriate box on the abstract form.

The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission to the Secretariat.

The Organisers reserve the right to remove from any publications an abstract which does not comply with the above.